Skip to main content

Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates.

Publication ,  Journal Article
Gillio, AP; Gasparetto, C; Laver, J; Abboud, M; Bonilla, MA; Garnick, MB; O'Reilly, RJ
Published in: J Clin Invest
May 1990

Interleukin-3 (IL-3) is a hematopoietic growth factor that supports the growth of early hematopoietic progenitors in vitro. In vivo administration of recombinant human interleukin-3 (rhIL-3) to normal primates results in a modest and delayed leukocytosis secondary to increases in neutrophils, basophils, and eosinophils. We postulated that the effects of rhIL-3 might be more pronounced in hematologically stressed primates, and therefore administered rhIL-3 to primates after intensive myelosuppressive therapy. Primates received either cyclophosphamide (CPM) at 60 mg/kg or 5-fluorouracil (5-FU) at 75 mg/kg i.v. on two consecutive days. Subsequently, rhIL-3 was administered intravenously or subcutaneously at 20 micrograms/kg per d for 14 d. Compared to controls, all rhIL-3 treated primates experienced higher absolute neutrophil count (ANC) nadirs and dramatic decreases in the period of severe neutropenia (ANC less than 500) after myelosuppressive therapy. RhIL-3 administration resulted in a significant basophilia and eosinophilia, which resolved after discontinuation of the drug. RhIL-3 did not enhance erythroid recovery. Platelet recovery was earlier in rhIL-3-treated animals. However, variations in the platelet recovery observed in control animals, precluded accurate estimation of this effect or its significance. Our results indicate that the administration of rhIL-3 following intensive myelosuppressive therapy dramatically enhances myeloid recovery and ablates the predicted period of prolonged severe neutropenia.

Duke Scholars

Published In

J Clin Invest

DOI

ISSN

0021-9738

Publication Date

May 1990

Volume

85

Issue

5

Start / End Page

1560 / 1565

Location

United States

Related Subject Headings

  • Recombinant Proteins
  • Neutrophils
  • Male
  • Macrophages
  • Macaca fascicularis
  • Leukocyte Count
  • Kinetics
  • Interleukin-3
  • Immunology
  • Hematopoietic Stem Cells
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gillio, A. P., Gasparetto, C., Laver, J., Abboud, M., Bonilla, M. A., Garnick, M. B., & O’Reilly, R. J. (1990). Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates. J Clin Invest, 85(5), 1560–1565. https://doi.org/10.1172/JCI114605
Gillio, A. P., C. Gasparetto, J. Laver, M. Abboud, M. A. Bonilla, M. B. Garnick, and R. J. O’Reilly. “Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates.J Clin Invest 85, no. 5 (May 1990): 1560–65. https://doi.org/10.1172/JCI114605.
Gillio AP, Gasparetto C, Laver J, Abboud M, Bonilla MA, Garnick MB, et al. Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates. J Clin Invest. 1990 May;85(5):1560–5.
Gillio, A. P., et al. “Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates.J Clin Invest, vol. 85, no. 5, May 1990, pp. 1560–65. Pubmed, doi:10.1172/JCI114605.
Gillio AP, Gasparetto C, Laver J, Abboud M, Bonilla MA, Garnick MB, O’Reilly RJ. Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates. J Clin Invest. 1990 May;85(5):1560–1565.

Published In

J Clin Invest

DOI

ISSN

0021-9738

Publication Date

May 1990

Volume

85

Issue

5

Start / End Page

1560 / 1565

Location

United States

Related Subject Headings

  • Recombinant Proteins
  • Neutrophils
  • Male
  • Macrophages
  • Macaca fascicularis
  • Leukocyte Count
  • Kinetics
  • Interleukin-3
  • Immunology
  • Hematopoietic Stem Cells